| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H27NO4 |
| Molar mass | 345.439 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both abeta blocker and acalcium channel blocker.[1][2] It wasdiscovered anddeveloped byWarner-Lambert[3] but in January 1989 the company announced that it had withdrawn theNew Drug Application; the company's chairman said: "Who needs the 30th beta blocker?"[4] As of 2016[update] it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.[5]
Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byadding missing information. |